Ignite Creation Date:
2025-12-24 @ 5:39 PM
Ignite Modification Date:
2026-04-22 @ 2:19 PM
Study NCT ID:
NCT06027268
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-17
First Post:
2023-08-31
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
Sponsor:
Wake Forest University Health Sciences
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
IRB00095334
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None